Xaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 Clinical Trial for Xaluritamig (AMG 509) in Advanced Prostate Cancer Set to Open for Recruitment Soon
/in Clinical Trial, Metastatic, Phase 3/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxPhase III Trial for Metastatic Castration-Resistant Prostate Cancer of an EZH2 inhibitor
/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026